TGF-β signalling-related markers in cancer patients with bone metastasis
Authors:
- Mace L. RothenbergMRMace L. Rothenberg
- Josep TaberneroJTJosep Tabernero
- Joan SeoaneJSJoan Seoane
- Thomas DalyTDThomas Daly
- Ann CleverlyACAnn Cleverly
- Brandi BerryBBBrandi Berry
- Susanne K. RhoadesSRSusanne K. Rhoades
- Chad A. RayCRChad A. Ray
- Jeffrey FillJFJeffrey Fill
- Daphne L. FarringtonDFDaphne L. Farrington
- Lisa Anne WallaceLWLisa Anne Wallace
- 1 January 2008
- journal article
- Published by Taylor & Francis in Biomarkers
- Vol. 13 (2) , 217-236
Abstract
We measured transforming growth factor (TGF)-beta-dependent biomarkers in plasma and in peripheral blood mononuclear cells (PBMCs) to identify suitable pharmacodynamic markers for future clinical trials with TGF-beta inhibitors. Forty-nine patients with bone metastasis were enrolled in the study, including patients with breast (n=23) and prostate cancer (n=15). Plasma TGF-beta1 levels were elevated in more than half of the cancer patients (geometric mean 2.63 ng ml(-1)) and positively correlated with increased platelet factor 4 (PF4) levels, parathyroid-related protein (PTHrP), von Willebrand Factor (vWF) and interleukin (IL)-10. PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-beta inhibitor.Keywords
This publication has 32 references indexed in Scilit:
- Development and validation of a phosphorylated SMADex vivostimulation assayBiomarkers, 2007
- Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-β Type I Receptor Kinase InhibitorCancer Research, 2006
- Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β InhibitorClinical Cancer Research, 2006
- β Thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosisAnnals of the Rheumatic Diseases, 2005
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Platelet factor 4 modulation of the thrombomodulin–protein C systemCritical Care Medicine, 2004
- TGF-β signaling: positive and negative effects on tumorigenesisCurrent Opinion in Genetics & Development, 2002
- von Willebrand factor antigen levels in plasma of patients with malignant breast diseaseBrazilian Journal of Medical and Biological Research, 2001
- Autocrine growth factors and cancerNature, 1985
- Increased plasma concentrations of platelet factor 4 in coronary artery disease: a measure of in vivo platelet activation and secretion.Circulation, 1981